Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Blood (2018) 132 (15): 1584–1592.

https://doi.org/10.1182/blood-2018-05-849059

Published: 2018

Includes: Supplemental data

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

Journal Articles

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report

Marijana Vujkovic, Edward F. Attiyeh, Rhonda E. Ries, Elizabeth K. Goodman, Yang Ding, Marko Kavcic, Todd A. Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Lillian Sung, Betsy Hirsch, Susana Raimondi, Alan S. Gamis, Soheil Meshinchi, Richard Aplenc

Blood (2017) 129 (23): 3051–3058.

https://doi.org/10.1182/blood-2017-03-772384

Published: 2017

Includes: Supplemental data

Journal Articles

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Blood (2013) 121 (21): 4366–4376.

https://doi.org/10.1182/blood-2012-10-464149

Published: 2013

Includes: Supplemental data

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Jessica Pollard, Todd Alonzo, Robert Gerbing, Rong Zeng, Betsy Hirsch, Susana Raimondi, Nyla Heerema, William Woods, Beverly Lange, Craig Hurwitz, Robert Arceci, Jerald Radich, Irwin Bernstein, Michael Heinrich, Soheil Meshinchi

Blood (2007) 110 (11): 1442.

https://doi.org/10.1182/blood.V110.11.1442.1442

Published: 2007

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.

Marilyn L. Slovak, Clara D. Bloomfield, Holly Gundacker, Gordon Dewald, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman, Cheryl Willman, Yaddanapudi Ravindranath, Todd A. Alonzo, Andrew Carroll, Betsy Hirsch, Susana Raimondi, Nyla A. Heerema

Blood (2004) 104 (11): 567.

https://doi.org/10.1182/blood.V104.11.567.567

Published: 2004

Journal Articles

Monosomy 7 and Deletion 7q in Childhood AML. A Collaborative Study of 20 Study Groups.

Blood (2004) 104 (11): 402.

https://doi.org/10.1182/blood.V104.11.402.402

Published: 2004

Journal Articles

Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment

Mary V. Relling, James M. Boyett, Javier G. Blanco, Susana Raimondi, Frederick G. Behm, John T. Sandlund, Gaston K. Rivera, Larry E. Kun, William E. Evans, Ching-Hon Pui

Blood (2003) 101 (10): 3862–3867.

https://doi.org/10.1182/blood-2002-08-2405

Published: 2003

Journal Articles

Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia

John T. Sandlund, Patricia L. Harrison, Gaston Rivera, Frederick G. Behm, David Head, James Boyett, Jeffrey E. Rubnitz, Amar Gajjar, Susana Raimondi, Raul Ribeiro, Melissa Hudson, Mary Relling, William Evans, Ching-Hon Pui

Blood (2002) 100 (1): 43–47.

https://doi.org/10.1182/blood.V100.1.43

Published: 2002

Journal Articles

Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation

Vladimir M. Belkov, Eugene Y. Krynetski, John D. Schuetz, Yuri Yanishevski, Eric Masson, Susan Mathew, Susana Raimondi, Ching-Hon Pui, Mary V. Relling, William E. Evans

Blood (1999) 93 (5): 1643–1650.

https://doi.org/10.1182/blood.V93.5.1643

Published: 1999

Journal Articles

All Patients With the T(11; 16)(q23; p13.3) That Involves MLL and CBP Have Treatment-Related Hematologic Disorders

Janet D. Rowley, Shalini Reshmi, Olatoyosi Sobulo, Tarannum Musvee, John Anastasi, Susana Raimondi, Nancy R. Schneider, Julio C. Barredo, Eduardo S. Cantu, Brigitte Schlegelberger, Frederick Behm, Norman A. Doggett, Julian Borrow, Nancy Zeleznik-Le

Blood (1997) 90 (2): 535–541.

https://doi.org/10.1182/blood.V90.2.535

Published: 1997

NARROW

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report

Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.

Monosomy 7 and Deletion 7q in Childhood AML. A Collaborative Study of 20 Study Groups.

Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment

Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia

Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation

All Patients With the T(11; 16)(q23; p13.3) That Involves MLL and CBP Have Treatment-Related Hematologic Disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only